Advancements in PROTAC Degraders Unveiled at AACR 2024

The recent AACR 2024 annual conference showcased groundbreaking research on PROTAC degraders, shedding light on their development, design, and application in targeted cancer therapy. This article presents a comprehensive overview of the latest advancements in PROTAC technology and its potential in revolutionizing the field of oncology.

1. From ADC to DAC: A Brief Overview of PROTAC Technology

At this year's AACR conference, Arvinas, a pioneering company in the PROTAC field, sponsored a session titled "From Chemistry to Clinic." The session focused on the combination of PROTAC and Antibody-Drug Conjugates (ADCs) and explored the synergistic advancements that arise from this integration. Notably, Marcel Rieker, a scientist from Merck Germany, presented an exciting concept of bridging PROTAC and ADC technologies to deliver degraders to diseased cells. Rieker's presentation introduced PROTAC-ADCs and self-assembling PROxAb shuttles, highlighting the innovative application of PROTAC technology in drug delivery system design. This research showcased the potential to enhance the selectivity and efficacy of therapeutics, thus holding significant implications for cancer treatment.

2. Understanding Degrader Antibody Conjugates (DACs)

A slide presented at the conference provided insights into the complex process of generating Degrader Antibody Conjugates (DACs). The slide depicted the key factors influencing DAC development, including the suitability of small molecule inhibitors for PROTAC technology and the introduction of E3 ligand and linker into the system. It emphasized the crucial steps in DAC construction, such as determining the optimal attachment points on PROTAC and potential chemical modifications. Additionally, the slide highlighted the importance of selecting the optimal conjugation sites and Drug-to-Antibody Ratio (DAR) in the antibody component to ensure the overall properties of the conjugate. The complexity of the process increases as it transitions from individual components to complete conjugates. Several critical aspects were mentioned, including the evaluation of conjugate quality, benefits of PROTAC-antibody conjugation, and the relevance of E3 ligase activity to the desired indications. Achieving a balance between plasma stability and intracellular release kinetics and understanding the impact of connector selection on DAC properties were also underscored.

3. Disulfide Bridges and Engineered Cysteines in ADC Development

The slide further discussed the significance of disulfide bridges and engineered cysteines in Antibody-Drug Conjugates (ADCs). Disulfide bridges, existing within antibody molecules, can serve as connecting points for efficient payload conjugation by exposing free cysteine residues upon reduction. Engineered cysteines, introduced through genetic engineering techniques, offer additional conjugation sites, reducing ADC heterogeneity and improving stability and therapeutic efficacy. The choice of appropriate attachment sites is crucial as it directly influences drug release and antibody functionality. Disulfide bridges and engineered cysteines provide a means to conjugate payloads to antibodies without compromising their structure and function. These advancements have positioned ADCs as a promising strategy for cancer treatment.

4. The PROxAb Shuttle Technology: A Non-Covalent Approach

The article also touched upon the PROxAb Shuttle technology, which relies on single-domain antibodies derived from camelids. These antibodies can bind to the VHL ligand binding subunit of PROTACs. By fusing this antibody domain with existing antibody scaffolds, bispecific fusion proteins can be created. The PROxAb Shuttle approach offers a non-covalent alternative to the covalent antibody-PROTAC conjugation, allowing for improved flexibility and potentially enhanced therapeutic efficacy.

The AACR 2024 conference provided a platform to showcase the latest advancements in PROTAC degraders, demonstrating their potential in targeted cancer therapy. The integration of PROTAC technology with ADCs and the development of DACs and PROxAb Shuttles offer innovative strategies for improving the selectivity, efficacy, and delivery of therapeutics. These advancements hold significant promise in advancing the field of oncology and bringing us closer to more effective cancer treatments.